HashKey aims for US$214 million in Hong Kong IPO amid Beijing’s crypto pressure


Crypto exchange operator HashKey Holdings has launched its share sale in Hong Kong, testing investor appetite amid repeated warnings against virtual currencies by China’s central bank.

Hong Kong’s largest licensed crypto player set its initial public offering (IPO) price range at HK$5.95 to HK$6.95 apiece for more than 240 million shares, according to a filing on Tuesday. The listing date is December 17.

With the price range, HashKey is eyeing up to HK$1.67 billion (US$214 million). In October, the firm was said to be aiming for US$500 million.

The People’s Bank of China has repeated its tough stance on cryptocurrency speculation, including stablecoins. It said it would maintain its ban on crypto trading and persistently crack down on illegal financial activities to guard against risks.
HashKey operates one of 11 virtual asset trading platforms recognised by Hong Kong’s Securities and Futures Commission. It is set to become the second crypto exchange operator to list in the city after OSL Group, following Hong Kong’s 2022 push to position itself as a global hub for digital assets. OSL shares have risen 18 per cent so far this month.
HashKey operates one of 11 virtual asset trading platforms recognised by Hong Kong’s Securities and Futures Commission. Photo: Handout
HashKey operates one of 11 virtual asset trading platforms recognised by Hong Kong’s Securities and Futures Commission. Photo: Handout

While cryptocurrencies remained volatile, licensed virtual asset platforms – with their revenue and profit records – allowed investors to make better judgements, helping support share price performance, said Kenny Ng Lai-yin, a strategist at Everbright Securities International.

  • Related Posts

    China’s AI red-packet battle burns through US$1 billion – but will users stick around?

    In an unprecedented Chinese New Year marketing blitz, Alibaba Group Holding, Baidu, ByteDance and Tencent Holdings spent an estimated 8 billion yuan (US$1.1 billion) to turn their artificial intelligence assistants…

    Continue reading
    Chinese AI drug researcher XtalPi expects to turn first annual profit on 193% revenue jump

    Chinese artificial intelligence-powered drug researcher XtalPi Holdings said it expects to turn its first annual profit on the back of strong revenue growth, according to a corporate filing. The Shenzhen-based…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *